Reuters logo
10 months ago
BRIEF-Nuvo receives approval from German regulators to conduct phase 3 trial for treatment of acute ankle sprains
October 17, 2016 / 11:52 AM / 10 months ago

BRIEF-Nuvo receives approval from German regulators to conduct phase 3 trial for treatment of acute ankle sprains

Oct 17 (Reuters) - Nuvo Pharmaceuticals Inc :

* Nuvo Pharmaceuticals receives approval from German regulatory authorities to conduct Pennsaid 2 pct phase 3 trial for treatment of acute ankle sprains

* Nuvo Pharmaceuticals Inc - topline results are expected to be available in Q2 2017

* Nuvo Pharmaceuticals Inc - 130 patient trial will be conducted in germany commencing this month

* Says trial is intended to support regulatory applications for marketing approval of pennsaid 2 pct in E.U., Canada and Australia

* Says it is in ongoing discussions with a number of potential international licensing partners

* Trial will cost approximately CDN$1.5 million spread over second half of 2016 and first half of 2017

* Nuvo - in ongoing discussions with potential international licensing partners that have commercial capabilities to effectively market Pennsaid 2 pct Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below